CIK 0001512762 · Accelerated filer<br>Smaller reporting company
Coherus Oncology, Inc.
Sign in to watch- Ticker
- CHRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273615821
- Phone
- (650) 649-3530
- Business address
- C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
- Former names
- Coherus BioSciences, Inc., BioGenerics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-07-10 | FINCK BARBARA K Chief Medical Officer | Option exercise | +1,260 | $1.42 | $2K | 38,303 |
| 2018-07-10 | FINCK BARBARA K Chief Medical Officer | Sale | −1,260 | $15.00 | $19K | 37,043 |
| 2018-07-10 | FINCK BARBARA K Chief Medical Officer | Option exercise · Stock Option (right to buy) | −1,260 | 86,461 | ||
| 2018-07-09 | FINCK BARBARA K Chief Medical Officer | Option exercise | +500 | $1.42 | $710 | 37,543 |
| 2018-07-09 | FINCK BARBARA K Chief Medical Officer | Sale | −500 | $15.03 | $8K | 37,043 |
| 2018-07-09 | FINCK BARBARA K Chief Medical Officer | Option exercise · Stock Option (right to buy) | −500 | 87,721 | ||
| 2018-06-18 | FINCK BARBARA K Chief Medical Officer | Option exercise | +1,760 | $1.42 | $2K | 38,803 |
| 2018-06-18 | FINCK BARBARA K Chief Medical Officer | Sale | −1,760 | $15.00 | $26K | 37,043 |
| 2018-06-18 | FINCK BARBARA K Chief Medical Officer | Option exercise · Stock Option (right to buy) | −1,760 | 88,221 | ||
| 2018-05-16 | Lanfear Dennis M See Remarks | Sale | −20,984 | $16.26 | $341K | 1,316,582 |
| 2018-05-14 | Anicetti Vincent R Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2018-05-09 | NUSSBAUM SAMUEL R MD Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2018-03-01 | Anicetti Vincent R Chief, Quality & Compliance | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2018-02-01 | HEALY JAMES Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2018-02-01 | Watler Peter K. Chief Technical Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2018-02-01 | Troendle August J. Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2018-02-01 | Szela Mary T Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2018-02-01 | LAWLIS V BRYAN Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2018-02-01 | FINCK BARBARA K Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +130,000 | 130,000 | ||
| 2018-02-01 | Viret Jean-Frederic Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +130,000 | 130,000 |
Page 23 of 39 · 768 trades